This Lexicon Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Cantor Fitzgerald Initiates Coverage On Lexicon Pharmaceuticals with Overweight Rating, Announces Price Target of $8
Lexicon Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:LXRX) 2026-08-10